These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 18398083)

  • 1. When should data and safety monitoring committees share interim results in cardiovascular trials?
    Borer JS; Gordon DJ; Geller NL
    JAMA; 2008 Apr; 299(14):1710-2. PubMed ID: 18398083
    [No Abstract]   [Full Text] [Related]  

  • 2. Regulatory perspectives on data safety monitoring boards: protecting the integrity of data.
    Hemmings R; Day S
    Drug Saf; 2004; 27(1):1-6. PubMed ID: 14720083
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recommendations for data monitoring committees from the Clinical Trials Transformation Initiative.
    Calis KA; Archdeacon P; Bain R; DeMets D; Donohue M; Elzarrad MK; Forrest A; McEachern J; Pencina MJ; Perlmutter J; Lewis RJ
    Clin Trials; 2017 Aug; 14(4):342-348. PubMed ID: 28503947
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Standard 3: data monitoring committees.
    Ellenberg S; Fernandes RM; Saloojee H; Bassler D; Askie L; Vandermeer B; Offringa M; Van der Tweel I; Altman DG; van der Lee JH;
    Pediatrics; 2012 Jun; 129 Suppl 3():S132-7. PubMed ID: 22661759
    [No Abstract]   [Full Text] [Related]  

  • 5. Independence of the statistician who analyses unblinded data.
    Siegel JP; O'Neill RT; Temple R; Campbell G; Foulkes MA
    Stat Med; 2004 May; 23(10):1527-9. PubMed ID: 15122732
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A major trial needs three statisticians: why, how and who?
    Pocock SJ
    Stat Med; 2004 May; 23(10):1535-9. PubMed ID: 15122734
    [TBL] [Abstract][Full Text] [Related]  

  • 7. University of Pennsylvania 10th annual conference on statistical issues in clinical trials: Current issues regarding data and safety monitoring committees in clinical trials (morning panel session).
    Davis B; Kerr D; Maguire M; Sanders C; Snapinn S; Wittes J
    Clin Trials; 2018 Aug; 15(4):335-351. PubMed ID: 30021495
    [No Abstract]   [Full Text] [Related]  

  • 8. Committee for Medicinal Products for Human Use (CHMP) guideline on Data Monitoring Committees.
    ; ;
    Stat Med; 2006 May; 25(10):1639-45. PubMed ID: 16639775
    [No Abstract]   [Full Text] [Related]  

  • 9. Data and safety monitoring boards: academic credit where credit is due?
    Armstrong PW; Califf RM
    JAMA; 2013 Oct; 310(15):1563-4. PubMed ID: 24129461
    [No Abstract]   [Full Text] [Related]  

  • 10. Data monitoring committees for pragmatic clinical trials.
    Ellenberg SS; Culbertson R; Gillen DL; Goodman S; Schrandt S; Zirkle M
    Clin Trials; 2015 Oct; 12(5):530-6. PubMed ID: 26374679
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reporting standards for adverse events after medical device use in the peripheral vascular system.
    Ouriel K; Fowl RJ; Davies MG; Forbes TL; Gambhir RP; Morales JP; Ricci MA;
    J Vasc Surg; 2013 Sep; 58(3):776-86. PubMed ID: 23972246
    [No Abstract]   [Full Text] [Related]  

  • 12. Clinical trial registration.
    Harms M
    Physiotherapy; 2011 Sep; 97(3):181. PubMed ID: 21820534
    [No Abstract]   [Full Text] [Related]  

  • 13. Research review boards dogged by criticism.
    Ledford H
    Nature; 2009 Apr; 458(7238):557. PubMed ID: 19340042
    [No Abstract]   [Full Text] [Related]  

  • 14. An introductory note to CHMP guidelines: choice of the non-inferiority margin and data monitoring committees.
    Brown D; Volkers P; Day S
    Stat Med; 2006 May; 25(10):1623-7. PubMed ID: 16639776
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Should statisticians reporting to data monitoring committees be independent of the trial sponsor and leadership?
    Ellenberg SS; George SL
    Stat Med; 2004 May; 23(10):1503-5. PubMed ID: 15122727
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An introductory note to the CHMP guidelines: choice of the non-inferiority margin and data monitoring committees by David Brown, Peter Volkers and Simon Day, Statistics in Medicine 2006; 25:1623-1627.
    Stat Med; 2007 Jan; 26(1):230-3; author reply 234-5. PubMed ID: 16900566
    [No Abstract]   [Full Text] [Related]  

  • 17. Board games.
    Nature; 2007 Aug; 448(7153):511-2. PubMed ID: 17671461
    [No Abstract]   [Full Text] [Related]  

  • 18. The independent statistician model: How well is it working?
    DeMets D
    Clin Trials; 2018 Aug; 15(4):329-334. PubMed ID: 29741390
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stopping guidelines for harm in a study designed to establish the safety of a marketed drug.
    Fleishman AN; Parker RA
    J Biopharm Stat; 2012; 22(2):338-50. PubMed ID: 22251178
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Conflicts of interest in data monitoring of industry versus publicly financed clinical trials.
    Lachin JM
    Stat Med; 2004 May; 23(10):1519-21. PubMed ID: 15122730
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.